Clostridium difficile can cause antibiotic-associated diarrhea in hospitalized patients. Asymptomatic colonization by C. difficile is common during the neonatal period and early infancy, ranging from 21% to 48%, and in childhood. The colonization rate of C. difficile in adult hospitalized patients shows geographic variation, ranging from 4.4% to 23.2%. Asymptomatic carriage in neonates caused no further disease in many studies, whereas adult patients colonized with toxigenic C. difficile were prone to the subsequent development of C. difficile-associated diarrhea (CDAD). However, the carriage of nontoxigenic C. difficile strains appears to prevent CDAD in hamsters and humans. Risk factors for C. difficile colonization include recent hospitalization, exposure to antimicrobial agents or gastric acid-suppressing drugs (such as proton-pump inhibitors and H2 blockers), a history of CDAD or cytomegalovirus infection, the presence of an underlying illness, receipt of immunosuppressants, the presence of antibodies against toxin B, and Toll-like receptor 4 polymorphisms. Asymptomatic C. difficile carriers are associated with significant skin and environmental contamination, similar to those with CDAD, and contact isolation and hand-washing practices should therefore be employed as infection control policies for the prevention of C. difficile spread. Treating patients
Introduction
Clostridium difficile is the leading cause of antibioticassociated diarrhea in hospitalized patients through the production of toxins A and B and, most likely, a binary toxin. The clinical manifestations range from mild diarrhea to pseudomembranous colitis, toxic megacolon, and even death. The incidence of C. difficile-associated diarrhea (CDAD) is increasing worldwide and in Taiwan. 1 In the USA, the reported case number of CDAD in 2005 (84/100,000) was nearly three times that in 1996 (31/100,000). The identified risk factors for CDAD include advanced age, 2,3 previous hospitalization, 2,4 the use of feeding tubes, 5 antimicrobial exposure, 2, 4, 6 and the use of proton pump inhibitors (PPIs). 4 Avoidance of unnecessary antimicrobial agents or gastric acid-suppressing agents, such as PPIs, in addition to contact isolation and hand washing, have been regarded as important infection control policies to prevent the spread of C. difficile in hospitals. 7 In addition to patients with CDAD, those with C. difficile colonization (CdC) have been regarded as potential reservoirs of C. difficile and it is a general belief that the number of patients colonized with C. difficile outnumbers that of patients with CDAD. 8 The incidence of CdC could be as high as 23 .2% among hospitalized patients, 9 particularly among vulnerable populations, such as patients with cystic fibrosis (32.4%) 10 (Table 1) . 8e10, 16,18e22,25,26,30,35,37,40e42,45e48 C. difficile isolates that are capable of producing toxins A and B are regarded as toxigenic; otherwise, they are considered nontoxigenic. Toxigenic C. difficile colonization (tCdC) has been described as an independent risk factor for the subsequent development of CDAD, 8, 9 and nontoxigenic C. difficile has been used to treat relapsing CDAD. 11 However, the clinical significance of tCdC or nontoxigenic CdC (ntCdC) remains controversial, warranting more attention from clinicians, infection control staff, epidemiologists, and microbiologists. In this review, we aim to elucidate the epidemiology, clinical impact, risk factors, and infection control concerns of individuals with tCdC or ntCdC.
Epidemiology of C. difficile colonization
During the neonatal period and early infancy, asymptomatic colonization by C. difficile is common, ranging from 21% to 48% in some reports, particularly among those with prolonged hospitalization, low birth weight (<2500 g), or younger gestational age (<37 weeks) as well as those nursing in an incubator or delivered by cesarean birth (Table 2) . 12, 14, 15, 49, 50 There was geographic variation in C. difficile colonization rates among infants, with 35% observed among Swedish infants compared to 4% in Estonian infants. 12 Infant susceptibility to C. difficile colonization may be due to the inability of their intestinal microbiota to resist CdC. Rousseau et al 13 have demonstrated that the presence of C. difficile in the gut of infants is associated with changes in the microbiota composition. CdC has also been noted during childhood, particularly among those with malignancy (19%) or inflammatory bowel disease (17%). 14, 15 Likewise, the colonization rates of C. difficile in adult hospitalized patients vary geographically. In Canada, as few as 4.4% of hospitalized patients had CdC at admission. 16 The prevalence rate of CdC has been reported as 4.4e3.3% in France, 7.9% in the UK, 2.1e18.4% in the USA, 14% in Israel, and 20e23.2% in Taiwan (Table 1) . However, the rates cannot be compared between these studies, as their study designs (prospective or retrospective), detection methods (culture, cytotoxin assay, or polymerase chain reaction), target populations, and/or the inclusion of ntCdC varied. In the study by Lee et al, 17 changing incidence and clinical manifestations of CDAD were noted when introduction of the combination of glutamate dehydrogenase and toxin assay in Northern Taiwan.
Because C. difficile is often acquired from a nosocomial environment, additional cases of CdC have been discovered during hospitalization, with the figures of CdC higher than those at admission or at initial screening. For example, the prevalence rate of CdC was 2.1% (11/517) at initial screening and 50% (64/128) during follow-up for more than 1 month in a study conducted by Clabots et al. 18 In our prospective study, we found a CdC prevalence rate of 20.0% among hospitalized patients at an initial screening, with an additional 25.4% of the patients developing CdC during follow-up. 8 Many reports have explored the prevalence rates of CdC among the elderly. In general, the elderly in nursing care units or long-term care facilities (LTCFs) had higher prevalence rates of CdC. Fecal CdC was detected in 4% of the elderly outside LTCFs in the UK 19 and in 0.6% of elderly individuals in Belgium. 20 Arvand et al 21 reported a typical finding that the prevalence of CdC was 4.6% (11/240) in nursing home residents versus 0.8% (2/249) in the elderly living outside LTCFs. However, such a figure may range from 10% in continuing care institutions 22 to 51% among LTCF residents. 23 With the increase in the elderly population worldwide, the potential clinical sources of C. difficile among the elderly, particularly those in LTCFs, require more clinical attention.
Other susceptible populations have been investigated in addition to the elderly, including individuals with cystic fibrosis, inflammatory bowel disease, or human immunodeficiency virus (HIV) infection. CdC has been noted in 32 .4% (12/37) of cystic fibrosis patients, compared to 7.5% (3/40) of control patients. 10 The greater extent of CdC may be related to younger age, more severe pulmonary disease, and more exposure to antimicrobial agents in cystic fibrosis patients, 24 in whom, for unknown reasons, C. difficile strains are often nontoxigenic (77% vs. 17%). Asymptomatic C. difficile carriage is significantly more prevalent among patients with inflammatory bowel disease than controls (17% vs. 3%, p Z 0.012). 15 It is surprising that there are few CdC data among HIVinfected patients. In a ward in which 74% of patients were HIV infected, Hutin et al 25 reported a CdC prevalence rate of 13.3% (32/240). In another study, the prevalence rate of CdC was 3.8% (2/52) among HIV-infected patients, which was lower than that in noneHIV-infected patients (4.4%, 3/ 68). 26 However, the prevalence rate of CdC in HIV-infected patients may have been underestimated, as both studies were conducted prior to 1998. By contrast, in a study in an HIV-infected cohort, the incidence of CDAD was 8.3 cases/ 1000 patient-years, which was twice that previously reported and increased independently of a CD4 cell count 50 cells/mL. 27 The prevalence rate and clinical impact of CdC in HIV-infected patients require further large-scale investigations.
tCdC and ntCdC: good or bad?
As described earlier, fecal carriage of C. difficile, either toxigenic or non-toxigenic, is common among neonates. Such a carrier state is well tolerated by infants, and the immunoglobulin G antitoxin response that develops during the carrier state appears to provide durable protection against subsequent C. difficile disease. 28 However, the clinical impact of CdC in adults remains unsettled. An early study suggested that CdC was associated with a low risk of CDAD 29 (Table 3) . 8, 9, 23, 29, 30, 40, 42 However, other studies have reported that patients with CdC are more likely to develop CDAD. 8, 9, 30 In a recent study, diabetes mellitus and prior receipt of piperacillinetazobactam or PPIs were found to be independent risk factors for the development of CDAD among hospitalized patients with tCDC. 31 These studies were diverse in study design, including the definition of diarrhea, toxigenic or nontoxigenic isolates, hospital settings, calendar years, follow-up periods, and antibiotic pressure, which may underlie the differences in their conclusions. The ability of hosts to mount an immune response might be a factor determining whether a patient with CdC will develop CDAD. Mulligan et al 32 found that immunoglobulin (Ig) A and IgM concentrations were significantly higher in asymptomatic carriers than in symptomatic patients. Another study found that asymptomatic carriers had greater increases in serum levels of IgG against toxin A and in serum levels of IgM against non-toxin antigens than did patients with CDAD. 30 The variable capability to mount immune responses can, at least partially, explain the different clinical evolutions among individuals acquiring C. difficile. The hypothesis that serum immunoglobulins against composite antigens of C. difficile can be used as surrogate markers of CDAD development among C. difficile carriers warrants further clinical study.
As early as in 1987, a promising result of oral therapy with nontoxigenic C. difficile was reported for difficult-totreat CDAD. Two patients with relapsing CDAD following metronidazole and vancomycin therapy were treated by a nontoxigenic C. difficile strain given orally, and both responded well without side effects. 11 However, the role of nontoxigenic C. difficile as a therapy is more controversial than its preventive use. Nontoxigenic C. difficile has been examined for the prevention of the establishment of toxigenic C. difficile in the intestinal tract in animal models, including hamsters. Pretreatment with nontoxigenic C. difficile protected hamsters from subsequent lethal challenge with toxigenic C. difficile. 33 Notably, an epidemiological survey revealed that the incidence of CDAD was low in individuals with ntCdC (0/34, 0%) and in those without colonization (3/328, 0.9%). 8 It is plausible that precolonization of the intestinal tract with nontoxigenic C. difficile can exclude toxigenic CdC by outcompeting the toxigenic C. difficile for a limiting nutrient. The ability of nontoxigenic C. difficile administration to prevent CDAD in animal models has prompted human clinical trials, which are in the early stages. Among these, an oral suspension of VP20621, spores of a nontoxigenic C. difficile strain (M3), are evaluated for its ability to protect against the colonization of human guts by toxigenic strains, and have been shown to be in good tolerability in healthy adults. 34 Risk factors of C. difficile colonization Because C. difficile is a nosocomial pathogen, it is not surprising that previous hospitalization is a risk factor for CdC, as revealed by several studies (Table  4 ). 8,9,15,16,18,23,25,35e37,40,41,45,50 For example, Loo et al 16 reported that patients with recent hospitalization, i.e., in the previous 2 months, were more likely to have CdC. Similarly, Eyre et al 35 found that CdC at admission was correlated with a hospital stay within the previous 6 months. Because there was an increased risk of CdC in hospitals, prolonged hospitalization is a likely risk factor for CdC. 36 Previous exposure to cephalosporins, 8, 37 penicillins, 25 clindamycin, 25 co-trimoxazole, 37 or fluoroquinolones 23 has been linked to CdC. However, the effects of cephalosporins on the development of CdC are diverse and dependent on the cephalosporin generation. We previously reported that prior prescription of cefepime, a fourth-generation cephalosporin, was associated with tCdC, whereas cefuroxime, a secondgeneration cephalosporin, was associated with ntCdC. 8 The use of gastric acid-suppressing drugs, including antacids, 19 PPIs, 15, 16 and H2 blockers, 16 is a risk factor CDAD in addition to nosocomial CdC because vegetative C. difficile can survive exposure to gastric contents with reduced acidity. 38 In addition, PPIs decrease extracellular and intracellular reactive oxygen production and the bactericidal activity of neutrophils, 39 which mediate the host defense against C. difficile.
Additional host variables related to CdC have been identified, including a history of CDAD 40 or cytomegalovirus infection, 40 hemodialysis, 41 the receipt of immunosuppressants 35 or corticosteroids, 35 renal insufficiency, 40 admission to vascular surgery services, 40 and liver transplantation. 40 Of interest, the presence of antibodies against toxin B has been associated with CdC. 16 However, many variables have not been consistently related to CdC in the literature. In our previous work, patients with the TLR4 rs1927914 polymorphism (GG genotype) had a higher risk of CdC. 8 These risk factors suggest that CdC is associated with the host's immune status.
Management of C. difficile colonization
In addition to CDAD, patients with CdC have been regarded as a reservoir of C. difficile contamination. In a study by Riggs et al, 23 51% of asymptomatic patients carried toxigenic C. difficile, of which 37% belonged to the epidemic strain. In the same study, compared with noncarriers, asymptomatic carriers had higher percentages of skin (61% vs. 19%; p Z 0.001) and environmental contamination (59% vs. 24%; p Z 0.004). Spores on the carriers' skin were easily transferred to their hands. Importantly, 87% of the isolates from the skin and 58% of isolates from the environment were matched to concurrent isolates in the stool. 23 By comparison, in CDAD patients in the Cleveland VA Medical Center (Cleveland, Ohio, USA), the prevalence of skin and/or environmental contamination was lower among asymptomatic carriers (3/18, 17% vs. 5/6, 83%; p Z 0.007), but the carriers outnumbered CDAD patients by a factor of 3:1. This finding underlines an important message: asymptomatic carriers have great potential to contribute to C. difficile transmission in hospitals. 42 Additionally, nosocomial acquisition of a C. difficile strain has been reported to be preceded by a documented introduction into the ward by another asymptomatic ward admission in 16 (84%) of 19 instances, suggesting that C. difficile-colonized new admissions are a major source of nosocomial C. difficile infections. 18 Thus, CdC may be a source for the nosocomial spread of C. difficile, but the detailed pathways by which it spreads should be carefully explored when designing infection control policies for CdC. In fact, there are voices in favor of C. difficile screening coupled with isolation precautions in terms of economic dominance and health benefits in hospitals.
Infection control for C. difficile colonization
Because environmental contamination is important for C. difficile spread from carriers, contact isolation and hand washing are essential infection control measures. 7 C. difficile spores survive routine environmental cleaning with detergents and hand hygiene practices using alcohol-based gels. 43 Enhanced environmental cleaning with 10% sodium hypochlorite and hand washing with chlorhexidine or soap and water can reduce C. difficile burden, and the use of barrier precautions can attenuate C. difficile transmission. 43 More aggressively, metronidazole and vancomycin have been used individually to eradicate CdC, although with discrepant results. In a study involving 30 asymptomatic C. difficile carriers, fecal C. difficile was absent during and immediately after oral vancomycin therapy in nine of 10 patients, compared to three of 10 patients treated by oral metronidazole (p Z 0.02) and two of 10 patients treated with placebo (p Z 0.005). Nevertheless, eight of nine patients with transient clearance of fecal CdC following vancomycin treatment excreted C. difficile again within an average of 20 days after completing treatment. 44 Therefore, the investigators did not favor antimicrobial eradication of CdC. There is no adequate evidence to support metronidazole or vancomycin therapy in the routine management of fecal colonization by C. difficile.
Conclusion
In conclusion, asymptomatic fecal colonization by C. difficile can cause skin and environmental contamination, similar to that observed among patients with CDAD, and more attention should be given to the clinical impact of C. difficile carriers and infection control policies.
